News
2d
Medpage Today on MSNCombo Semaglutide-Amylin Analogue Boosts Weight Loss Regardless of DiabetesCHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...
Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...
Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...
21h
News-Medical.Net on MSNCagrilintide and semaglutide together drive record weight loss in global trialA 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...
Danish drugmaker Novo Nordisk has launched its popular weight-loss drug Wegovy in India, months after its rival Mounjaro’s ...
Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...
Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as ...
In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...
Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...
Infection, delayed kidney function, kidney loss and death are all risks associated with kidney transplant surgery in obese ...
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...
A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results